Dyne Therapeutics, INC Form 4 insider transactions

Director Jason Rhodes reported sales of Dyne Therapeutics (DYN) common stock on March 1, 2024, executed under pre-arranged Rule 10b5-1 trading plans.

Atlas Venture Opportunity Funds I and II sold shares of Dyne Therapeutics (DYN) at $30.05 per share under pre-arranged Rule 10b5-1 trading plans.

Dyne Therapeutics CEO Joshua Brumm exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Jonathan McNeill, Chief Business Officer of Dyne Therapeutics, reports the sale of common stock and exercise of stock options, according to a recent SEC Form 4 filing.

Richard Scalzo, SVP, Head of Finance & Admin. at Dyne Therapeutics, reported exercising stock options and selling shares of common stock on February 29, 2024, and March 1, 2024, under a pre-arranged 10b5-1 trading plan.

Director Jason Rhodes reports the sale of Dyne Therapeutics (DYN) common stock through multiple transactions executed under pre-arranged Rule 10b5-1 trading plans.

Atlas Venture Funds, a significant shareholder in Dyne Therapeutics, executed multiple sales of common stock between February 26 and February 28, 2024, under pre-arranged Rule 10b5-1 trading plans.

Wildon Farwell, Chief Medical Officer of Dyne Therapeutics, sold 407 shares of common stock at $25 per share on February 28, 2024, according to a Form 4 filing with the SEC.